CIMIT Gives Academic Community Voice In Least Burdensome Debate
This article was originally published in The Gray Sheet
Executive SummaryThe Center for Innovative Minimally Invasive Therapy (CIMIT) is planning a public forum that will convene representatives from FDA, industry and the academic community to discuss the "least burdensome" process for device evaluation in several specific product areas.
You may also be interested in...
Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.